Mepolizumab
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
- Mepolizumab
- Mepolizumab: From Hypereosinophilic Syndrome to Thrombocytopenia Due to Immune Destruction
以下是根據 Evidence Pack 產生的藥師評估報告：
Mepolizumab: From Hypereosinophilic Syndrome to Thrombocytopenia Due to Immune Destruction
One-Sentence Summary
Mepolizumab is an anti-IL-5 monoclonal antibody used internationally for eosinophilic conditions including severe eosinophilic asthma and hypereosinophilic syndrome (HES); it is not currently approved in Taiwan. The TxGNN model predicts it may be effective for thrombocytopenia due to immune destruction, with 0 clinical trials and 1 case report currently supporting this direction. The mechanistic link is indirect and context-dependent, applicable only in the narrow setting of HES-complicated thrombocytopenia.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypereosinophilic syndrome / Eosinophilic conditions (international approval; not approved in Taiwan) |
| Predicted New Indication | Thrombocytopenia due to immune destruction |
| TxGNN Prediction Score | 99.66% |
| Evidence Level | L4 |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known information, mepolizumab is an anti-IL-5 monoclonal antibody that blocks interleukin-5 (IL-5), the cytokine primarily responsible for eosinophil proliferation, activation, and survival. By depleting circulating eosinophils, mepolizumab prevents eosinophil-mediated end-organ damage, including tissue infiltration and the release of toxic granule proteins.
The proposed mechanistic bridge to immune-mediated thrombocytopenia runs through HES: activated eosinophils in HES release cytotoxic granule proteins — eosinophil cationic protein (ECP) and major basic protein (MBP) — which can physically damage platelet membranes, drive platelet consumption, and trigger secondary immune-mediated platelet destruction. In this highly specific scenario, reducing the eosinophil burden with mepolizumab may indirectly improve platelet counts.
Critically, this pathway is indirect and context-dependent. Mepolizumab does not directly address the core mechanisms of primary immune thrombocytopenic purpura (ITP), such as anti-GPIIb/IIIa autoantibodies or T-cell-mediated platelet destruction. The TxGNN prediction is therefore plausible only when thrombocytopenia arises as a complication of active HES — not as a standalone therapy for primary ITP.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28648630 | 2018 | Case Report | Blood Cells, Molecules & Diseases | Mepolizumab resolved steroid-resistant hypereosinophilic immune diathesis in a patient with atypical hemolytic uremic syndrome (aHUS), with concurrent amelioration of mixed thrombotic microangiopathy — suggesting that eosinophil-mediated platelet pathology may be partially reversible with IL-5 blockade. |
Taiwan Market Information
Mepolizumab is currently not approved or marketed in Taiwan. No TFDA authorization records are on file.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The sole piece of supportive evidence is a single case report in a highly unusual, multi-system clinical context (aHUS + HES + thrombotic microangiopathy); there are no registered clinical trials and no systematic data linking mepolizumab to immune-mediated platelet destruction in a general patient population.
To proceed, the following is needed:
- MOA documentation: Retrieve full mechanism of action from DrugBank (DG002) to strengthen the mechanistic rationale
- Taiwan safety data: Download and parse the TFDA package insert to complete warnings and contraindications assessment (DG001)
- Patient subpopulation definition: Clearly define the target cohort as "HES-associated immune thrombocytopenia" rather than primary ITP, to narrow the clinical hypothesis
- Prospective case series or observational study: At least a multi-centre case series is needed before advancing to a formal clinical trial design
- International regulatory review: Confirm whether any HES-complicated thrombocytopenia cases have been captured in the EMA or FDA post-marketing surveillance data for mepolizumab
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.